Hims & Hers saw a dramatic premarket rise in its stock after reports emerged that Novo Nordisk plans to make its obesity medications available through the telehealth company's platform, a development that may also bring an end to the legal dispute between the two firms.
Late on Friday, a news report said Novo and Hims were preparing to announce a partnership. The same report indicated that such an agreement would likely resolve Novo's recent patent-infringement lawsuit against Hims, which followed the U.S. telehealth firm's earlier launch - and subsequent cancellation - of a purported $49 copy of Novo’s obesity pill.
The regulatory backdrop added pressure to Hims' actions: the U.S. Food and Drug Administration had reportedly threatened action against the telehealth company related to the product roll-out and removal.
Market reaction was swift. Hims shares were up 54% premarket, trading at $24.20, while U.S.-listed shares of Novo saw only marginal gains. Analysts noted the market's response reflected relief that a protracted and expensive legal battle might be avoided.
Michael Cherny of Leerink characterized the reports as an unexpected but plainly favorable development for Hims' stock, which had been facing the prospect of a drawn-out legal contest. Cherny observed that the potential deal suggests Novo is broadening its distribution strategy and that Hims’ large consumer base would be an attractive channel for the drug maker once legal issues are resolved.
However, the economics for Hims remain unclear. Barclays analysts wrote that if the deal is confirmed, Hims could provide members with access to NovoCare Pharmacy at about $149 per month for the obesity drug. That pricing, Barclays said, would likely generate much lower margins for Hims than the company receives from its compounded offerings.
Despite the margin uncertainty, Barclays added that any agreement avoiding a multi-year trial would be a net positive for Hims. The firms have a recent history of a short-lived distribution arrangement: last year Novo ended its brief agreement to sell Wegovy through Hims, citing concerns about Hims' marketing tactics and ongoing sales of Wegovy copies.
The news item also included promotional material about an AI stock-screening service, noting that one can evaluate NovoNordisk (NVO) alongside other companies using a variety of financial metrics. That promotional content highlighted the AI's approach to identifying risk-reward opportunities but does not alter the reported market and legal developments between Novo and Hims.
Summary - Reports that Novo Nordisk may distribute its weight-loss medications via Hims’ telehealth platform triggered a major premarket rally in Hims shares and could signal a settlement of Novo’s patent lawsuit; the commercial and margin outcomes for Hims remain uncertain.